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Background: First generation drug-eluting stents have shown differential efficacy in high-risk patient subsets at 1-year. It is unclear whether these 
differences endure over the long-term. We compared the 5-year clinical efficacy and safety of sirolimus-eluting stents (SES; Cypher) and paclitaxel-
eluting stents (PES; Taxus) in a population of high-risk patients pooled from 3 randomized controlled trials.
Methods: The patient cohorts of the ISAR-DIABETES, ISAR-DESIRE and ISAR-SMART-3 randomized trials were followed-up for 5 years after 
enrolment and data were pooled. The primary endpoints of the analysis were the need for revascularisation of the target lesion (efficacy) and death 
or myocardial infarction (MI) (safety) during a five-year follow-up period.
Results: A total of 810 patients (405 in the SES and 405 in the PES group) were included in the analysis. Over 5 years target lesion 
revascularisation (TLR) was reduced by 39% with SES compared to PES stent (Fig. 1). Definite stent thrombosis occured in 0.2% (n=1) in the SES 
and in 1.6% (n=6) in the PES group (RR 0.16; 95% CI, 0.03-1.03; p=0.05). However, no difference was observed according to death or MI rates 
between the two groups (Fig. 2).
Conclusions: In high-risk patient subsets the anti-restenotic efficacy advantage of SES over PES is maintained out to 5 years. In terms of safety, 
there was a trend towards more frequent stent thromboses with PES, without influencing the overall incidence of death or MI.
